Amarantus BioSciences, Inc. is focused on the discovery and development of therapeutic proteins with the potential to address critically important biological pathways involved in the treatment human diseases.
The Company’s lead program MANF is aimed at developing products to address the underlying Programmed Cell Death (Apoptosis) associated a wide range of devastating human disorders. With a global trend towards an prolonged life expectancy due to novel therapies and emerging countries gaining access to critical medical care, the development of Apoptosis-related treatments represents a significant market opportunity that addresses a critical unmet medical need: safely and effectively improving currently-approved patients treatments.
Amarantus’ business strategy, utilizing Amarantus’ seasoned Management Team, world-class Scientific Advisory Board and Board of Directors, is to employ our PhenoGuard Drug Discovery Engine to discover medically-relevant secreted human proteins, scientifically establish their therapeutic potential, develop pre-clinical and clinical programs to further their development, and advance them through successive de-risking milestones to maximize their commercial potential while making them attractive partnering targets for product development focused biotechnology, pharmaceutical, medical device and diagnostic companies
News 
Market Data 
Discover 
AI
